Background Gaps in the diagnostic capacity and heterogeneity of national surveillance and reporting standards in Europe make it diffi cult to contain carbapenemase-producing Enterobacteriaceae. We report the development of a consistent sampling framework and the results of the fi rst structured survey on the occurrence of carbapenemaseproducing Klebsiella pneumoniae and Escherichia coli in European hospitals.
Introduction
Carbapenemase-producing Enterobacteriaceae (CPE) are the most pervasive antibiotic resistance threat to health services worldwide. Because of the dearth of alternative drugs, patients are often left without eff ective treatment, revealing burgeoning resistance, long concealed by adaptive prescribing when doctors could still choose carbapenems as a last-line drug. Therefore, spread of CPE could be the tipping point when substantial morbidity and mortality from antibiotic resistance comes to the fore. 1 Few alternative antibiotics (eg, colistin, fosfomycin, and tigecycline) remain, 2 and although resistance can extend even to agents still in development or recently approved, 3, 4 public health eff orts are beginning to emphasise containment of CPE in populations and health-care networks. This requires an understanding of the geographical distribution of CPE infections, their population reservoirs, and the risk factors for acquisition. However, there is little internationally comparable data.
The European Survey on CPE (EuSCAPE) was initiated with the aim of providing the fi rst comparable and quality-controlled data on the occurrence of the most important CPE (Klebsiella pneumoniae and Escherichia coli) in Europe and neighbouring countries, and to establish a framework for future enhanced sentinel surveillance. It entailed the stepwise build-up of structures through identifi cation of national expert laboratories (NELs), 5 a joint agreement on diagnostic standards, improvement of quality-assessed diagnostic capacity among NELs, and, as a proof of feasibility, a structured survey using a standard sampling protocol in all participating sites. We describe the execution and fi nal results of the EuSCAPE structured survey.
with EUCAST guidelines. 6 Subsequently, all NELs were required to take part in an external quality assessment exercise, which was carried out and analysed by the UK National External Quality Assessment Service. Successful completion was a prerequisite for participation.
Structured survey
Each NEL recruited a defi ned number of hospitals with microbiologic diagnostic capacity, depending on the country's population; 20 sites were recruited in large countries (>15 million population), ten sites in mediumsized countries (2-15 million population), and one site in small countries (<2 million population). To prevent geographical bias, the NELs were asked to enrol hospitals in a geo-demographical representative manner (fi gure, appendix). NELs were asked to collect additional information about the participating hospitals for 2013, including number of beds, annual number of admissions, total number of patient-days, average bed occupancy, average length of stay, and estimated size of catchment population.
The sampling period was 6 months, starting on Nov 1, 2013, and ending on April 30, 2014. During this period, each sentinel site was required to collect the fi rst ten consecutive primary isolates of K pneumoniae or E coli from clinical specimens from individual patients if local routine tests showed non-susceptibility to any carbapenem (imipenem, meropenem, or ertapenem). All clinical specimens were accepted, except for stool and surveillance screening samples. Each index isolate (ie, carbapenem-non-susceptible K pneumoniae or E coli) was matched to the fi rst subsequent carbapenem-susceptible isolate of the same species irrespective of anatomical site, serving as a comparator isolate.
Isolates were dispatched to the NEL with additional information including sample date, anatomical origin of specimen, patient age and sex, clinical relevance of the isolate (colonisation or infection), patient location in the hospital (intensive care unit, ordinary ward, outpatient, or accident and emergency), and hospital admission and travel outside their country of residence in the past 6 months. Hospital acquisition was inferred when an isolate was sampled from patients after being admitted for more than 48 h, or community-associated otherwise. Instructions on the collection of isolates, and the ascertainment of clinical and epidemiological data were given by the structured survey protocol (appendix), which was translated by NELs into their respective language and distributed to the sentinel hospital laboratories if necessary.
The NELs confi rmed species and phenotypic susceptibility and used PCR tests for four carbapenemase gene families (Klebsiella pneumoniae carbapenemase [KPC], New Delhi metallo-β-lactamase [NDM], oxacillinase-48 [OXA-48-like], or Verona integronencoded metallo-β-lactamase [VIM]). Antimicrobial susceptibility tests according to EUCAST guidelines variously included ampicillin, amoxicillin and clavulanic acid, piperacillin and tazobactam, cefotaxime, ceftazidime, cefepime, aztreo nam, imipenem, mero penem, ertapenem, cipro fl oxacin, trimethoprim and sulfamethoxazole (co-trimoxazole), genta micin, amikacin, tobramycin, tigecycline, colistin, and fosfo mycin. Phenotypic confi rmation of carbapenemase production consisted of double disk synergy tests, com bin ation disk tests, and Carba NP I or II test. 7 Metho dological details for these tests are described in the appendix. Carbapenem non-susceptible isolates that were tested PCR-negative
Research in context
Evidence before this study On April 1, 2016, we search Pubmed with the terms "carbapenemase-producing Enterobacteriaceae" or "carbapenem-resistant Enterobacteriaceae", or "Klebsiella pneumoniae", "Escherichia coli", "Europe" and "surveillance" for reports published between Jan 1, 2000 and Jan 1, 2016, with no language restrictions. This search identifi ed 72 publications. These consisted of larger national surveillance studies, reviews, or single case studies. None of the studies included comprehensive European coverage, standardisation of methods, or diagnostic quality assessment. Before this study, only anecdotal evidence existed for several countries with high endemicity. Since national reference laboratory structures were often absent and diagnostic standards diff ered between laboratories, cases remained unconfi rmed leaving wide scope for ascertainment bias.
Added value of this study
We report data on the occurrence of carbapenemaseproducing and last-line antibiotic resistant K pneumoniae and E coli using standardised procedures and provide the fi rst comparable and laboratory-substantiated data on the incidence of these diffi cult-to-treat bacteria across Europe.
Implications of all the available evidence K pneumoniae of nosocomial provenance is the main source of carbapenemase-producing Enterobacteriaeceae (CPE) infection in Europe. The emergence and spread of antibiotic resistance against last-line antibiotics increasingly erodes the ability to successfully treat patients infected with CPE especially in countries where CPE prevalence in hospitals is high. At a time when novel and eff ective antibiotic compounds have not become available, containment of CPE is bound to rely on stricter infection control measures in hospitals. were classifi ed as "other". Results and epidemiological information were uploaded for central analysis using a password-protected web tool.
All data were anonymised and collected in accordance with the European Parliament and Council decisions on the epidemiological surveillance and control of communicable disease in the European Community. 8, 9 Ethical approval and informed consent were thus not required.
Data analysis
Data were analysed with STATA version 13.1 (StataCorp, Texas, USA) using Mantel-Haenzel odds ratios and Pearson χ² test for univariate risk factor analysis and multiple logistic regression for multivariable analysis with log likelihood ratio tests after fi tting interaction terms to identify eff ect modifi cation. For hospitals that could not provide fi gures on the total number of patient days in 2013, we estimated this value as the product of the number of admissions and the average length of stay. Country-aggregated period prevalence estimates were reported as number of patients diagnosed with either carbapenemase-producing K pneumoniae or E coli per 10 000 hospital admissions. Country-aggregated incidence estimates were reported as number of patients diagnosed with either carbapenemase-producing K pneumoniae or E coli per 100 000 hospital patient-days. Confi dence intervals for random errors are not provided because of heterogeneity of sampling density as a result of diff erent diagnostic habits.
Role of the funding source
The study was funded by the European Centre for Disease Prevention and Control (ECDC) through a specifi c framework service contract (ECDC/2012/055) to the University Medical Center Groningen, Groningen, Netherlands. ECDC provided comments on the study design, suggested national coordinators, and provided comments on the analysis and the fi nal report. The decision to submit for publication was jointly taken by all contributors.
Results
Between Nov 1, 2013, and April 30, 2014, 455 sentinel hospitals from 36 countries contributed to the Iceland, Kosovo, and Sweden did not fi nd any K pneumonia isolates that were suspected non-susceptible to carbapenems during the study period. *Other mechanism of carbapenem non-susceptibility, since none of the genes coding for the four major types of carbapenemases (KPC, NDM, OXA-48-like and VIM) were detected. All data are n, except where otherwise indicated. 
Confi rmed carbapenemase-producing E coli isolates
Other (n, %)* Iceland, Kosovo, Latvia, Luxembourg, Montenegro, Poland Romania, and Macedonia did not fi nd any E coli isolate that was suspected non-susceptible to carbapenems during the study period. *Other mechanism of carbapenem non-susceptibility since none of the genes coding for the four major types of carbapenemases (KPC, NDM, OXA-48-like and VIM) were detected. Data are n, unless specifi ed otherwise. 12 (33%) of the NELs tested the full panel of 18 recom mended antibiotics. Some NELs found it diffi cult to obtain particular compounds, others used their routine reference service panel, and Denmark did not report any antibiotic susceptibility test results. Last-line antibiotics tested included colistin (tested in 22 NELs), tigecycline (tested in 20 NELs), and fosfomycin (tested in 18 NELs).
For K pneumoniae, the proportion of isolates that were reported resistant to all antibiotics varied between zero and 29% (mean 9%, table 4). Resistance to colistin was reported in 183 (28%) of 646 K pneumoniae isolates, fosfomycin resistance in 270 (54%) of 500 isolates, and tigecycline resistance (according to its EUCAST recommended breakpoint) in only 29 (5%) of 555. High proportions of K pneumoniae resistant to last-line antibiotics were found in Italy, Romania, Turkey, and Spain (table 4). Of the 77 E coli with carbapenemases, 57 were tested for susceptibility to colistin with three being resistant, 43 to fosfomycin (two isolates resistant), and 48 to tigecycline (one isolate resistant).
Carbapenem-susceptible comparator isolates of the same species were collected irrespective of anatomical site from clinical material submitted for diagnostic purposes from successive patients. These provided an important and unbiased sample, representative of the local susceptible population, and served as an appropriate control group. Univariate analysis identifi ed six risk factors that were positively associated with carbapenemase-producing K pneumoniae or E coli, and two factors that were negatively associated (appendix). Four of these risk factors remained signifi cantly and independently associated with carba penemase-producing K pneumoniae or E coli in the multi variable model, which included intensive care therapy (OR=1·9, 95% CI 1·4-2·7), hospital admission in the preceding 6 months (OR=2·0, 1·5-2·7), hospital-acquisition (OR=2·6, 1·9-3·7), and travel outside the country of residence in the previous 6 months (OR=3·0, 1·6-5·7).
Discussion
Clinicians increasingly depend on carbapenem antibiotics for the treatment of infections due to otherwise multidrug-resistant bacteria. CPE have been implicated in hospital outbreaks and have the propensity to spread (or disseminate their plasmids) rapidly at local, regional, and international levels. [10] [11] [12] [13] [14] [15] We provide comprehensive survey results on the occurrence of carbapenemase-producing K pneumoniae and E coli between Nov, 2013, and April, 2014, from 455 hospitals in 34 European countries plus Turkey and Israel, together serving more than 270 million citizens out of a total population of 600 million. During the course of this investigation, NELs successfully expanded their capacity and adjusted workfl ows to accommodate new diagnostic tests. 16 However, as with all sampling frameworks for bacteria and epidemiological data, important caveats remain. Despite decisions to minimise workload by concentrating on the two clinically most relevant species and reducing the amount of additional information, nine countries failed to recruit their quota of sentinel sites and an another eight countries did not provide crucial denominator data. In some cases this was because of fi nancial constraints and because the workload could not be accommodated by some of the hospital laboratories that had initially agreed to participate. Some NELs with established routines could not manage to test additional antibiotics. As with other international surveillance systems (EARS-Net), this study relied on routinely available data. The precision of some of the estimates on the occurrence and risk factors of CPE in the European region could therefore still be improved. For example, some countries reported low numbers of index CPE isolates when, judging from previous publications and high endemicity in neighbouring countries, much higher rates would have been expected. In these countries, diagnostic habits might result in a lower sampling density or the recruited sentinel sites were less able to reliably identify carbapenem-non-susceptible isolates despite testing profi ciency of the NELs, concealing the true incidence of CPE through these types of ascertainment bias. Moreover, 353 (29%) of 1203 K pneumoniae isolates and 117 (60%) of 194 E coli isolates that were submitted by the sentinel hospital laboratories as suspected carbapenem-non-susceptible had none of the four major carbapenemases (KPC, NDM, OXA-48-like, and VIM) and were reported as other. This lack of specifi city could be the result of a carbapenemase not included in the test panel, or alternative mechanisms such as reduced permeability. At the same time, sentinel laboratories relied on their local routine antibiotic susceptibility tests that might also be the source of potential misclassifi cation. Nevertheless, these fi rst data on CPE generated in a comprehensive manner will serve as a benchmark against which future initiatives and trends will be measured.
Prevalence of carbapenemase-producing K pneumoniae and E coli per 10 000 hospital admissions ranged from 6·0 in Italy, to 0·02 in Norway with an average of 1·3. The incidence per 100 000 hospital patient-days ranged from 17·3 in Greece to 0·09 in Lithuania, a mean of 2·5 across all countries. These values will underestimate total CPE incidence, because carba penemases also occur in other Enterobacteriaceae, albeit less frequently than in Klebsiella spp. 17 Moreover, the absence of denominator data from eight countries cautions against our ranking of prevalence. Proportions of carbapenemase-positive bacteria considered in this study varied between countries and between the two species under investigation (table 2, table 3 ). This might be the result of the diff erential success of certain clonal lineages in diff erent countries. 10, 14 We found a clear association with health care since most isolates were either acquired in hospital, often associated with intensive care treatment, or isolated from patients with previous hospital admission. We also found an association with previous travel outside the country of residence (appendix). But when interpreting this fi nding, we must consider that many of the highly endemic countries could not provide information on previous travel, which might have led to an infl ation of the risk estimate.
Incidence of carbapenemase-producing K pneumoniae and E coli was highest in southern and southeastern Europe. In Greece, VIM-positive K pneumoniae started to expand in the mid-2000s, 18 but that changed with the rapid spread of KPC-producing K pneumoniae from around 2007, which subsequently became the dominant CPE. 10 That NDM is now the second-ranking carbapenemase in Greece is striking and raises the concern that there could be a further replacement event by the more recently expanding carbapenemase. 19 Carbapenemase-producing isolates were less common in E coli than in K pneumoniae. KPC enzymes were especially rare in E coli and were only identifi ed in countries with high proportions of KPC-producing K pneumoniae, where they probably refl ect a spill-over of resistance genes from the K pneumoniae reservoir. Large numbers of E coli with OXA-48-like enzymes were found in Belgium, France, Spain, Turkey, and the UK, and NDM carba penemases in Bulgaria and Serbia. Penetration into E coli is of concern because E coli spreads in the com munity more readily than K pneumoniae, meaning that infection control interventions that mainly focus on hospitals are less likely to be eff ective. Moreover, E coli from the digestive tract are common vectors for promiscuous plasmids, which could also accelerate epidemic expansion.
In Romania, eight of 12 participating hospitals submitted K pneumoniae isolates with OXA-48-like enzymes and most were genetically indistinguishable by DNA fi ngerprinting, indicating countrywide spread of a single clone. 20 This fi nding might be analogous to the national expansion of K pneumoniae ST258-related clones with KPC-2 or KPC-3 enzymes in Greece, Italy, and Israel, for example, although with a diff erent clonal lineage and carbapenemase type. OXA-48-like carbapenemases were frequent in Malta, Spain, France, and Belgium, where they appear to be repeatedly introduced from northern Africa. Genes coding for NDM seem also to be spreading in the Balkan region, with large numbers in Montenegro, Serbia, and Greece but also extending north into Slovenia and Austria. Surprisingly, no NDM-producing isolates were reported from Albania, Kosovo, or Macedonia, despite their occurrence in adjacent countries and reports from patients transferred from these countries to other European countries. 21 Only 12 countries tested the complete panel of antibiotics recommended by the study protocol, which makes it diffi cult to establish the extent to which extensively drug-resistant or pan-drug-resistant Enterobacteriaceae phenotypes prevail in European hospitals. 22 Clinically more important than these epithets are the proportions of carbapenemase-producing isolates that are also resistant to last-line antibiotics such as colistin, fosfomycin, and tigecycline. We generally observed that high-CPE-incidence countries saw more resistance to these last-line antibiotics as well, perhaps refl ecting greater use and selection pressure. However, there were exceptions. Germany, which has a moderate CPE incidence, reported much higher rates of colistin and fosfomycin resistance than other moderate incidence countries. More worrying is the fact that the overall proportions of fosfomycin resistance (54%) and colistin resistance (28%) have become so high among carbapenemase-producing K pneumoniae that even the socalled colistin-plus treatment regimens favoured for infections due to CPE are increasingly jeopardised, leaving little choice in many cases. 23, 24 As exemplifi ed with this structured survey, the EuSCAPE project documented an encouraging degree of commitment from NELs, and shows that the political and logistical challenges of establishing a framework of enhanced sentinel surveillance for CPE can be overcome in Europe, Turkey, and Israel. There were large variations across Europe with respect to the distribution of the four major types of carbapenemases among clinical isolates of K pneumoniae and E coli. Clinicians should pay attention to antibiotic susceptibility testing results and be alerted when isolates show any degree of carbapenem nonsusceptibility, which would require confi rmation of carbapenemase production. For most isolates, there were still alternative options for patient treatment; however, resistance to all tested antibiotics was also reported, which is another reminder of the urgent need for prevention and control of CPE in Europe and emphasises the need for novel antibacterial agents that are active against carbapenem-resistant bacteria.
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